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Brachytherapy
160Gy dose-escalation in I-125 prostate implants: Updated outcomes and toxicity
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Introduction. D90 of 145Gy was adopted as the standard for I-125 seed implants. Dose-escalation in EBRT beneﬁt is widely
demonstrated for prostate cancer.
Objective. The aim of this dose escalating study (from D90>145Gy to D90>160Gy) is to analyze the biochemical recurrence-free
survival (bRFS) and toxicity proﬁle of prostate cancer patients treated with I-125 seeds implant.
Materials and methods. From January 08 to December 10, 219 low-risk and one factor intermediate-risk patients were chosen for
160Gy I-125 therapies. Previous MRI, urinary ﬂowmetry and IPSS questionnaire were realized. Using real-time intraoperative
interactive planning, prescribed dose was 160Gy, keeping the same urethral and rectal constraints as when 144Gy was the
prescribed dose. One month post-implant CT and MRI were realized for post-planning. Median age was 68 years old (range
41–79), median PSA 7.7ng/ml (range 2–33) and median Gleason 6. 79 patients were treated with hormone therapy (HT) (media
duration 4 months). Median US prostate volume was 35 cm3 (range 10–72). Retrospectively maximal acute and chronic toxicity,
using CTCv4.0 and RTOG scales, and bRFS, using Phoenix deﬁnition, were evaluated.
Results. The incidence of grade 3–4 acute toxicity was 3% (8 patients required urinary catheter because of acute retention, all
solved with medical treatment). No grade 3–4 chronic toxicity was observed. 73% of patients remained sexual function. 13 (6%)
patients presented biochemical failure. All patient with negative complementary exams (12/13) underwent to trans-perineal
prostate saturation biopsy, always, at least, 2 years after treatment. One of them presented histological failure and salvage
treatment with a new seed implant (120Gy) was done. Unique distant failure was an isolated bone metastasis treated with HT
and SBRT.
Conclusion. Dose escalation to 160Gy in I-125 prostate implants does not give rise more toxicity than 145Gy. Clinical results are
encouraging, but with a short follow-up.
http://dx.doi.org/10.1016/j.rpor.2013.03.702
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Introduction. Most recurrences alter breast conserving surgery occur within the index cuadrant despite the presence of multi-
centric cancers elsewhere in the breast. Thus, partial breast irradiation might be adequate for selected patients. High dose rate
brachytherapy (HDR-BT) is a feasible and comfortable technique for this partial approach.
Aim. After previous experience using HDR-BT as a boost, the aim of the study was to evaluate the feasibility, clinical results and
toxicity of HDR-BT delivered following the national protocol from SEOR Brachytherapy Group.
Methods. Between 2002 and 2013, 95 patients with early stage breast cancer were treated after conservative surgery with HDR-BT
using metallic needles adapted to surgical bed, with CT-based 3D dosimetry, delivering a dose of 32Gy in 8 fractions of 4Gy, as
the unique adjuvant radiation treatment.
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Results. From the 95 patients treated, we analyse the subgroup of 85 patients who had enough follow-up to evaluate late toxicity.
The mean age at treatment was 67 (range 45–92). Most of the tumors were located at external superior cuadrant (41.2%) or joint
of superior cuadrants (15.3%). Eighty per cent were inﬁltrating ductal carcinomas with an 84.7% of stage IA tumors and 70% of
luminal A molecular subtypes. Only 6 patients were grade 3, they were treated with HDR-BT due to their age. Fifty-one patients
received adjuvant hormonal therapy. Most patients (70.6%) were treated using 7 needles (range 4–12) in 2–3 planes, with a mean
active length of 4.5 cm (range 2–7 cm). With a mean follow-up of 23.47 months (range 6–124), only one patient has experimented
a recurrence in the ipsilateral breast 21 months after the procedure, she had a triple negative tumor and was treated with
mastectomy without disease nowadays. Three patients died from another non-related disease (cerebral-vascular stroke), none
of them died from breast cancer disease. Late toxicity was mild, with 27% and 5% of grade I cutaneous and subcutaneous toxicity
respectively.
Conclusions. Accelerated partial breast irradiation using HDR-BT is a proper approach, with excellent results in terms of disease
free survival and very good tolerance in terms of normal tissue late toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.703
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Purpose. Low dose rate (LDR) prostate brachytherapy is an accepted, effective and safe therapy for localized prostate cancer in
patients with transurethral resection. We analyzed oncologic outcome, side-effects and complications after I-125 brachytherapy
based on 11 years of experience.
Methods and materials. Between June 2000 and December 2005, 56 consecutive patients were treated with clinically localized
prostate cancer. No patients received external beam radiation. All of them underwent LDR prostate brachytherapy. Biochemi-
cal failure was deﬁned according to the “Phoenix consensus”. Patients were stratiﬁed as intermediate risk based on D’Amico
deﬁnition.
Results. The median follow up time for these 56 patients was 100 months; 2 had a clinical relapse and 4 had biochemical relapse.
The 11-year actuarial biochemical control was 92%, (SD ±3%) for overall group. The multivariate Cox regression analyses no
identiﬁed, independent prognostic factors for biochemical failure. The actuarial biochemical control with Gleason score was 93%
and 88% for patients with Gleason score of ≤6 and =7, respectively. The biochemical control was 95%, and 85% for patients with
PSA of ≤10 and >20ng/ml, respectively. A patient reported incontinence after treatment (1,7%). Acute urinary retention was seen
in 2 (3.5%). Gastrointestinal toxicity grade III–IV has been observed in 2 patients (3.5%).
Conclusions. The excellent long-term results and low morbidity presented, as well as the many advantages of prostate brachyther-
apy over other treatments, demonstrates that brachytherapy is an effective treatment for patients with transurethral resection
and clinical organ-conﬁned prostate cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.704
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Purpose/objective. Study the blood supply of uveal melanoma as a sign of tumoral activity and quantify its presence after
brachytherapy.
Materials and methods. 50 cases treated with brachytherapy were reviewed from July 2005 to June 2010. Mean follow-up was 29
months (13.7–69 months). Duplex Doppler scans (gray scale and Doppler scans) were done at diagnosis and every 6 months after
treatment. Presence of intratumoral vessels, maximum systolic and diastolic velocity and resistance index were evaluated. The
average age was 60 years; 26 ♂ and 24 ♀. Mean basal size and thickness at diagnosis were 12.1mm×5.6mm (SD 3.0–5.6). The
most used plaque was COMS type. Apical dose was 85Gy.
Results. Doppler detected intratumoral vascularization at diagnosis in 21/50 cases, 7 persisted at 6, 12 and 18 months, to 24
months 5/31, 30 months 3/20, 36 months 1/12, 42 months 1/6, 48 months 1/3, 54 months 1/2 and 60 months 0/1. Mean systolic
